Search the Newsreel

Diversified Management Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ

Diversified Management Inc. significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) by 61.1% in the second quarter, selling 12,147 shares and leaving its holdings valued at $1.96 million. This comes as Johnson & Johnson reported stronger-than-expected Q2 earnings and raised its full-year outlook, …

This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026

Quick Read PEY requires 10 straight years of dividend growth before yield ranking, and it delivered roughly 25% in 2026, which is nearly double the S&P 500's gain. Altria has raised its dividend 60 consecutive times over 56 years, while Johnson & Johnson just …

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

Johnson & Johnson (JNJ) is currently trading near its 52-week high, with analysts giving it a "Hold" rating due to its strong performance and pipeline balanced by valuation concerns and some declining product lines. While the company projects double-digit growth by the decade's end, …

Pronóstico semanal de las acciones de Johnson & Johnson: El impulso se mantiene con MACD alcista y volatilidad estable

Does Johnson & Johnson Stock Have More Upside?

What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders

In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The …

Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

Watch Johnson & Johnson’s Healthcare Conference Chat Sept. 14

Johnson & Johnson (NYSE: JNJ) announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Management will host a Fireside Chat at 11:30 a.m. Eastern Time, which will be accessible via a live audio webcast on the …

140-year-old Dividend King eyes bold update to unlock new growth

Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you …

ASC GPO inks deal with J&J for cardiac electrophysiology tech

Access GPO has finalized a deal with Johnson & Johnson for cardiac electrophysiology technologies, including pulsed field and radiofrequency ablation, 3D mapping, and intracardiac imaging. This partnership aims to enhance ASCs' capabilities in cardiac care. The agreement was announced on August 10, 2026.

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

This Insider Has Just Sold Shares In Johnson & Johnson

Johnson & Johnson's CEO & Chairman, Joaquin Duato, recently sold US$13m worth of stock at US$258 per share, representing a 14% decrease in his holding. This follows an earlier sale this year at a lower price of US$221 per share. While the sales are …

Johnson & Johnson (JNJ) Stock Analysis: Evaluating Its 5.11% Potential Upside

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings

Ist Johnson & Johnson (JNJ) Nach Starken Darzalex Lizenzgebühren Jetzt Voll Bewertet?

Johnson & Johnson EVP forminard sells $4.09m in stock

Johnson & Johnson (JNJ) Aktienanalyse & Prognose

Análisis y previsión de acciones de Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Johnson & Johnson (JNJ) Could Be a Great Choice

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow …

Noticias de acciones de Johnson & Johnson (JNJ)

Johnson & Johnson: what the healthcare giant makes and does

Johnson & Johnson is a global healthcare giant, founded in 1886, that now focuses primarily on pharmaceuticals and medical devices after spinning off its consumer health division, Kenvue, in 2023. The company's operations span Innovative Medicine (pharmaceuticals) and MedTech segments, with a significant emphasis …

Guggenheim raises Johnson & Johnson stock price target on new products

The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulence

Key Points Johnson & Johnson has historically been a safe haven during turbulent times. Coca-Cola, like J&J, is a Dividend King with a record of resilience. Chevron is an energy giant with a huge AI tailwind.10 stocks we like better than Johnson & Johnson …

Johnson & Johnson (JNJ) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Johnson & Johnson (JNJ) Picks Tom Cavanaugh As Jennifer Taubert Plans 2026 Retirement

Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced …

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson (NYSE: JNJ) announced its participation in the 2026 Wells Fargo Healthcare Conference. Management will host a Fireside Chat on Wednesday, September 9, 2026, at 11:00 a.m. Eastern Time. A live audio webcast and an archived replay will be available on the …

The $85 Billion Consolation Prize For JNJ Shareholders

Photo by Rigby40 on Pixabay The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them. Over the last five years, Johnson & Johnson (JNJ) sent $85 …

Johnson & Johnson-Aktie hält sich knapp über der Unterstützung bei 250,92 $, während widersprüchliche Signale anhalten: Wöchentliche Analyse

Johnson & Johnson stock holds just above $250.92 support as conflicting signals persist: weekly analysis

Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, is set to retire after a distinguished 21-year career, during which she significantly grew the company's Innovative Medicine business to over $60 billion in annual revenue. Tom Cavanaugh, currently Company Group …

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

NEW BRUNSWICK, N.J., August 04, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, …